FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018663191> ?p ?o ?g. }

• W2018663191 endingPage "20" @default.
• W2018663191 startingPage "16" @default.
• W2018663191 abstract "Cisplatin (Cp) plus topotecan (Tc) is the first combination chemotherapy to demonstrate a survival advantage over cisplatin alone in advanced cervical cancer. Combining Cp and Tc with an epidermal growth factor receptor (EGFR) inhibitor such as cetuximab (Ce) may increase the activity of chemotherapy.Patients with advanced cervical squamous cell cancer or adenocarcinoma and at least one measurable target received intravenous Cp 50 mg/m(2) on day 1 plus Tc 0.75 mg/m(2)/day from days 1 to 3 every 3 weeks combined with Ce (initial dose of 400 mg/m(2) followed by subsequent weekly dose of 250 mg/m(2)). Objective response rate according to RECIST criteria was the primary end point; safety, progression free survival (PFS) and overall survival (OS) were secondary end points.Between April and July 2007, 19 out of the 44 planned patients were accrued before the study was stopped early due to excessive toxicity. The most frequent adverse event was severe myelosuppression with grades 3-4 neutropenia (72%), grades 3-4 thrombocytopenia (61%), and grade 3 anemia (44.5%). The main grades 3-4 non-hematologic toxicities were infection (39%) and febrile neutropenia (28%), skin reactions (22%), renal toxicity (11%), and pulmonary embolism (11%). Five (28%) patients died during the treatment including 3 deaths related to treatment toxicity. Six (32%) evaluable patients achieved a partial response. The median times of PFS and OS were 172 and 220 days, respectively.In this phase II trial, the combination Cp-Tc-Ce induced a high rate of serious adverse and/or fatal events at standard dose and schedule. Cetuximab plus platinum-based combination chemotherapy should be further explored with caution in the future in advanced cervix cancer." @default.
• W2018663191 created "2016-06-24" @default.
• W2018663191 creator A5004452040 @default.
• W2018663191 creator A5018378577 @default.
• W2018663191 creator A5021695281 @default.
• W2018663191 creator A5025011731 @default.
• W2018663191 creator A5042166901 @default.
• W2018663191 creator A5065564812 @default.
• W2018663191 creator A5070962149 @default.
• W2018663191 creator A5071292317 @default.
• W2018663191 creator A5073063132 @default.
• W2018663191 creator A5084236822 @default.
• W2018663191 date "2009-04-01" @default.
• W2018663191 modified "2023-10-18" @default.
• W2018663191 title "Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial" @default.
• W2018663191 cites W2082601735 @default.
• W2018663191 cites W2090401278 @default.
• W2018663191 cites W2093207065 @default.
• W2018663191 cites W2103174300 @default.
• W2018663191 cites W2112845420 @default.
• W2018663191 cites W2119209952 @default.
• W2018663191 cites W2129944002 @default.
• W2018663191 cites W2136871952 @default.
• W2018663191 cites W2139248078 @default.
• W2018663191 cites W2142564546 @default.
• W2018663191 cites W2155384808 @default.
• W2018663191 cites W2157838504 @default.
• W2018663191 cites W2171725862 @default.
• W2018663191 doi "https://doi.org/10.1016/j.ygyno.2008.12.040" @default.
• W2018663191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19232434" @default.
• W2018663191 hasPublicationYear "2009" @default.
• W2018663191 type Work @default.
• W2018663191 sameAs 2018663191 @default.
• W2018663191 citedByCount "74" @default.
• W2018663191 countsByYear W20186631912012 @default.
• W2018663191 countsByYear W20186631912013 @default.
• W2018663191 countsByYear W20186631912014 @default.
• W2018663191 countsByYear W20186631912015 @default.
• W2018663191 countsByYear W20186631912016 @default.
• W2018663191 countsByYear W20186631912017 @default.
• W2018663191 countsByYear W20186631912018 @default.
• W2018663191 countsByYear W20186631912019 @default.
• W2018663191 countsByYear W20186631912020 @default.
• W2018663191 countsByYear W20186631912021 @default.
• W2018663191 countsByYear W20186631912022 @default.
• W2018663191 countsByYear W20186631912023 @default.
• W2018663191 crossrefType "journal-article" @default.
• W2018663191 hasAuthorship W2018663191A5004452040 @default.
• W2018663191 hasAuthorship W2018663191A5018378577 @default.
• W2018663191 hasAuthorship W2018663191A5021695281 @default.
• W2018663191 hasAuthorship W2018663191A5025011731 @default.
• W2018663191 hasAuthorship W2018663191A5042166901 @default.
• W2018663191 hasAuthorship W2018663191A5065564812 @default.
• W2018663191 hasAuthorship W2018663191A5070962149 @default.
• W2018663191 hasAuthorship W2018663191A5071292317 @default.
• W2018663191 hasAuthorship W2018663191A5073063132 @default.
• W2018663191 hasAuthorship W2018663191A5084236822 @default.
• W2018663191 hasConcept C121608353 @default.
• W2018663191 hasConcept C126322002 @default.
• W2018663191 hasConcept C141071460 @default.
• W2018663191 hasConcept C143998085 @default.
• W2018663191 hasConcept C197934379 @default.
• W2018663191 hasConcept C203092338 @default.
• W2018663191 hasConcept C2776694085 @default.
• W2018663191 hasConcept C2777063308 @default.
• W2018663191 hasConcept C2777240266 @default.
• W2018663191 hasConcept C2778220009 @default.
• W2018663191 hasConcept C2778239845 @default.
• W2018663191 hasConcept C2778248108 @default.
• W2018663191 hasConcept C2778850193 @default.
• W2018663191 hasConcept C2779998722 @default.
• W2018663191 hasConcept C2781209748 @default.
• W2018663191 hasConcept C29730261 @default.
• W2018663191 hasConcept C31760486 @default.
• W2018663191 hasConcept C526805850 @default.
• W2018663191 hasConcept C535046627 @default.
• W2018663191 hasConcept C71924100 @default.
• W2018663191 hasConcept C90924648 @default.
• W2018663191 hasConceptScore W2018663191C121608353 @default.
• W2018663191 hasConceptScore W2018663191C126322002 @default.
• W2018663191 hasConceptScore W2018663191C141071460 @default.
• W2018663191 hasConceptScore W2018663191C143998085 @default.
• W2018663191 hasConceptScore W2018663191C197934379 @default.
• W2018663191 hasConceptScore W2018663191C203092338 @default.
• W2018663191 hasConceptScore W2018663191C2776694085 @default.
• W2018663191 hasConceptScore W2018663191C2777063308 @default.
• W2018663191 hasConceptScore W2018663191C2777240266 @default.
• W2018663191 hasConceptScore W2018663191C2778220009 @default.
• W2018663191 hasConceptScore W2018663191C2778239845 @default.
• W2018663191 hasConceptScore W2018663191C2778248108 @default.
• W2018663191 hasConceptScore W2018663191C2778850193 @default.
• W2018663191 hasConceptScore W2018663191C2779998722 @default.
• W2018663191 hasConceptScore W2018663191C2781209748 @default.
• W2018663191 hasConceptScore W2018663191C29730261 @default.
• W2018663191 hasConceptScore W2018663191C31760486 @default.
• W2018663191 hasConceptScore W2018663191C526805850 @default.
• W2018663191 hasConceptScore W2018663191C535046627 @default.
• W2018663191 hasConceptScore W2018663191C71924100 @default.

• next